CLINICAL TRIALS PROFILE FOR CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER

All Clinical Trials for Cefotaxime And Dextrose 3.9% In Plastic Container

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00124228 ↗	Albumin Administration in Patients With Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis	Completed	Fondo de Investigacion Sanitaria	Phase 3	2004-11-01	Spontaneous bacterial peritonitis (SBP) present in cirrhotic patients induces severe circulatory dysfunction, which results in renal failure in up to 30% of the patients. Renal failure is an important prognostic marker, representing the major predictive factor of in-hospital mortality. Recent studies have shown that plasma volume expansion with albumin associated with cefotaxime in patients with SBP is more efficient to prevent renal failure than cefotaxime treatment alone. The in-hospital and three-month mortality rates, furthermore, were significantly lower in the group treated with albumin. It is not known if other bacterial infections unrelated to SBP represent a risk factor for the development of renal failure among cirrhotic patients. The researcher's group has recently performed a study to evaluate the incidence, characteristics and outcome, of renal failure in patients with cirrhosis and bacterial infections unrelated to SBP associated with the systemic inflammatory response syndrome (Terra, unpublished results). Among a total of 106 patients, 29 (27%) presented renal failure during the course of infection. Renal failure was characterized by intense renal vasoconstriction (intrarenal resistive index of 0.83 +/- 0.09, measured by Doppler ultrasound), reduction of mean arterial pressure and an important activation of endogenous vasoconstriction systems. The three-month survival probability of patients with infection and renal failure was 34 %, much lower than that of patients with infection but not presenting renal failure (87%, p
NCT00124228 ↗	Albumin Administration in Patients With Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis	Completed	Hospital Clinic of Barcelona	Phase 3	2004-11-01	Spontaneous bacterial peritonitis (SBP) present in cirrhotic patients induces severe circulatory dysfunction, which results in renal failure in up to 30% of the patients. Renal failure is an important prognostic marker, representing the major predictive factor of in-hospital mortality. Recent studies have shown that plasma volume expansion with albumin associated with cefotaxime in patients with SBP is more efficient to prevent renal failure than cefotaxime treatment alone. The in-hospital and three-month mortality rates, furthermore, were significantly lower in the group treated with albumin. It is not known if other bacterial infections unrelated to SBP represent a risk factor for the development of renal failure among cirrhotic patients. The researcher's group has recently performed a study to evaluate the incidence, characteristics and outcome, of renal failure in patients with cirrhosis and bacterial infections unrelated to SBP associated with the systemic inflammatory response syndrome (Terra, unpublished results). Among a total of 106 patients, 29 (27%) presented renal failure during the course of infection. Renal failure was characterized by intense renal vasoconstriction (intrarenal resistive index of 0.83 +/- 0.09, measured by Doppler ultrasound), reduction of mean arterial pressure and an important activation of endogenous vasoconstriction systems. The three-month survival probability of patients with infection and renal failure was 34 %, much lower than that of patients with infection but not presenting renal failure (87%, p
NCT00161330 ↗	Oral vs Initial Intravenous Antibiotic Treatment of Urinary Tract Infections in Children: a RCT	Terminated	IL Sogno di Stefano	Phase 3	2000-06-01	The main objectives of the study are 1. to compare the efficacy of oral vs initial iv antibiotic treatment in children with a first episode of UTI 2. to assess the diagnostic power of the various imaging technique (renal ultrasonogram, voiding cystourethrogram, and renal scanning with technetium-99m-labeled dimercaptosuccinic acid)
NCT00161330 ↗	Oral vs Initial Intravenous Antibiotic Treatment of Urinary Tract Infections in Children: a RCT	Terminated	Regione Veneto	Phase 3	2000-06-01	The main objectives of the study are 1. to compare the efficacy of oral vs initial iv antibiotic treatment in children with a first episode of UTI 2. to assess the diagnostic power of the various imaging technique (renal ultrasonogram, voiding cystourethrogram, and renal scanning with technetium-99m-labeled dimercaptosuccinic acid)

Clinical Trial Conditions for Cefotaxime And Dextrose 3.9% In Plastic Container

Condition Name

Condition Name for Cefotaxime And Dextrose 3.9% In Plastic Container
Intervention	Trials
Spontaneous Bacterial Peritonitis	4
Urinary Tract Infections	4
Respiratory Tract Infections	3
Sepsis	3

Condition MeSH

Condition MeSH for Cefotaxime And Dextrose 3.9% In Plastic Container
Intervention	Trials
Infections	9
Peritonitis	8
Infection	8
Communicable Diseases	6

Clinical Trial Locations for Cefotaxime And Dextrose 3.9% In Plastic Container

Trials by Country

Trials by Country for Cefotaxime And Dextrose 3.9% In Plastic Container
Location	Trials
Egypt	8
Spain	6
France	4
Sweden	3
Vietnam	2

Trials by US State

Trials by US State for Cefotaxime And Dextrose 3.9% In Plastic Container
Location	Trials
Virginia	1

Clinical Trial Progress for Cefotaxime And Dextrose 3.9% In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Cefotaxime And Dextrose 3.9% In Plastic Container
Clinical Trial Phase	Trials
PHASE4	2
Phase 4	14
Phase 3	7

Clinical Trial Status

Clinical Trial Status for Cefotaxime And Dextrose 3.9% In Plastic Container
Clinical Trial Phase	Trials
Completed	20
Recruiting	7
Unknown status	6

Clinical Trial Sponsors for Cefotaxime And Dextrose 3.9% In Plastic Container

Sponsor Name

Sponsor Name for Cefotaxime And Dextrose 3.9% In Plastic Container
Sponsor	Trials
Assistance Publique - Hôpitaux de Paris	2
Tanta University	2
Xiangbei Welman Pharmaceutical Co., Ltd	2

Sponsor Type

Sponsor Type for Cefotaxime And Dextrose 3.9% In Plastic Container
Sponsor	Trials
Other	54
Industry	3
OTHER_GOV	1

Cefotaxime And Dextrose 3.9% In Plastic Container Market Analysis and Financial Projection

Last updated: April 28, 2026

Cefotaxime and Dextrose 3.9% in Plastic Container: Clinical Trial Update, Market Analysis, and Projection

What is the product and what pipeline signals exist?

“Cefotaxime and Dextrose 3.9% in Plastic Container” is a compounded injectable format where cef​otaxime is formulated with dextrose (3.9%) for administration in a plastic container. In practice, this product is typically positioned as a ready-to-use or packaged dilution vehicle for cefotaxime therapy in hospital settings. The clinical development profile is usually tied to the established cefotaxime active ingredient rather than to a standalone reformulation brand-new molecular entity.

Across global markets, cef​otaxime is an established cephalosporin with long-standing clinical use; most “updates” in later years stem from:

• Formulation / container / stability work (plastic container compatibility, shelf-life extension, reconstitution/dilution handling).
• Regulatory lifecycle updates (manufacturing changes, packaging/label revisions).
• Pharmacovigilance and real-world evidence rather than new Phase 3 efficacy trials.
• Antimicrobial stewardship and comparative effectiveness, often framed around guideline adherence more than new cefotaxime trials.

What do the clinical trial updates typically include for this category?

For cefotaxime-containing injections, the trials landscape tends to show:

• Bioavailability is usually not the focus because injectable cefotaxime is administered parenterally and efficacy is demonstrated via standard pharmacodynamic targets rather than oral exposure metrics.
• Comparability studies dominate for formulation/packaging changes: stability, potency, appearance, pH, degradant profile, and container-closure integrity.
• Microbiological endpoint studies focus on susceptibility and pharmacodynamic breakpoint attainment rather than new clinical endpoints in later-stage programs.

At the market level, that means pipeline visibility is often indirect: manufacturers file supplemental approvals for packaging and manufacturing updates, while academic and surveillance efforts update resistance patterns.

---

Clinical Trials Update: What matters commercially?

1) Trial type signals that move market outcomes

For “cef​otaxime + dextrose” plastic-container products, the commercial impact usually tracks to four categories:

1. Stability and compatibility
   • Potency retention over shelf-life
   • Degradant control (cef​otaxime breakdown products)
   • Plastic container leachables/adsorption profile
2. Container-closure integrity
   • Sterility assurance and particulate control
   • Risk-management for handling in hospital workflows
3. Label and administration guidance changes
   • Infusion rates
   • Reconstitution steps (if any)
4. Resistance and stewardship positioning
   • Shifts in preferred empirical regimens by guideline and payer formularies

2) What to expect in Phase 2-3 economics for an established drug

Because the active ingredient is mature, new late-phase trials rarely reset market structure unless:

• A new clinical indication is pursued with regulatory-grade evidence.
• A clinically meaningful antimicrobial strategy shift drives renewed guideline inclusion.
• A major competitor supply disruption changes procurement patterns.

For many jurisdictions, procurement is driven by:

• Tender pricing
• Availability and lead time
• Formulary position for “cef​otaxime IV”
• Sourcing reliability for hospital distribution centers

---

Market Analysis: How big is this category and what drives demand?

Demand drivers

Cefotaxime IV demand in hospital channels tends to be driven by:

• Hospital antibiotic utilization for susceptible Gram-negative infections
• Empiric therapy protocols for specific patient populations and local resistance patterns
• Competition with other cephalosporins and beta-lactams
  • Ceftriaxone
  • Ceftazidime
  • Piperacillin-tazobactam
  • Carbapenems (as stewardship targets)

Key structural demand constraints

• Resistance dynamics: rising ESBL prevalence reduces usefulness in some empiric settings unless combined with appropriate stewardship.
• Stewardship restrictions: payers and hospital committees can tighten access to narrower agents when broader regimens are preferred.
• Unit cost vs administration format: plastic container format can reduce handling complexity and waste, improving tender desirability even at similar drug price.

Procurement reality

For sterile injectables, procurement decisions typically prioritize:

• Availability
• Shelf-life
• Packaging format (plastic container usability)
• Total cost of care (nursing time, preparation waste, administration time)

The dextrose component (3.9%) is functionally a vehicle and isotonic modifier. Buyers generally evaluate it as a formulation attribute tied to:

• infusion compatibility
• patient suitability (e.g., glucose handling considerations)
• stability during storage and administration

---

Market Projection: What is the likely trajectory?

Projection framework for established IV antibiotics

For mature antibiotics, market projection usually follows:

• Volume growth from baseline hospital admissions (modest)
• Volume erosion from stewardship and resistance constraints (structural headwind)
• Price adjustments driven by tender cycles and competitor entries
• Switching effects within cephalosporins and beta-lactams based on guideline and susceptibility trends

Most likely direction for cefotaxime “IV + dextrose plastic container”

• Mid-single-digit annual value volatility dominated by tender pricing and supply conditions.
• Low to mid single-digit volume changes depending on local resistance and guideline placement.
• Relatively stable procurement if formulary access remains intact, because hospitals treat cefotaxime as a dependable broad-spectrum option within susceptibility boundaries.

---

Competitive and Regulatory Landscape: What determines winners?

What differentiates products in a mature category

Even with an established active ingredient, procurement differentiation is driven by:

• Container and handling performance
• Shelf-life and stability proof strength
• Consistency of supply in tenders
• Regulatory resilience (fast supplemental approvals for manufacturing changes)
• Pharmacovigilance history and batch-to-batch consistency

Where “plastic container” tends to matter

Plastic container formats can carry procurement advantages:

• reduced breakage risk vs glass
• simplified nursing handling
• potentially improved compatibility with infusion workflows

The commercial edge is often operational rather than efficacy-based.

---

Business Implications for R&D and Investment

R&D: where the feasible upside usually sits

For cefotaxime IV formulations, incremental R&D that can improve commercial odds tends to focus on:

• Stability extension (longer shelf-life under specified storage)
• Container compatibility improvements (adsorption, extractables, leachables)
• Label workflow simplification (clear administration steps)
• Improved particulates control and sterility assurance

Investment: what to diligence

Investors should diligence around:

• manufacturing redundancy and sterile fill-finish capacity
• tender track record and distributor relationships
• batch yield and deviation rates (sterile manufacturing economics)
• regulatory history for supplemental approvals and manufacturing changes

---

Key Takeaways

• “Cefotaxime and Dextrose 3.9% in Plastic Container” is an established cefotaxime injectable where commercial outcomes typically hinge on formulation stability, container performance, and hospital procurement dynamics rather than new efficacy trials.
• Clinical trial visibility in this category often reflects comparability and stability work tied to lifecycle changes, plus ongoing resistance and stewardship pressure shaping guideline use.
• Market trajectory for mature IV antibiotics is usually stable but price- and tender-sensitive, with volume influenced by local resistance patterns and formularies.
• The main commercial differentiation for plastic-container presentations is operational reliability: shelf-life, availability, handling workflow, and regulatory consistency.

---

FAQs

1) Are new Phase 3 trials expected for cefotaxime + dextrose plastic container?

For an established active ingredient, late-phase trials are generally uncommon unless a new indication or clinically novel regimen is pursued. Most updates are lifecycle and formulation-led.

2) What does the “dextrose 3.9%” component change?

It functions primarily as a formulation vehicle and isotonic modifier, influencing stability and infusion compatibility rather than introducing a new therapeutic mechanism.

3) What best predicts hospital purchasing behavior for this product type?

Availability, shelf-life, container-handling performance, and tender pricing usually dominate over small formulation differences.

4) How do resistance trends affect the market?

Rising resistance, including ESBL prevalence, can reduce cefotaxime suitability in empiric protocols and shift utilization toward other beta-lactams or carbapenems, depending on guideline pathways.

5) What is the most investable angle in mature cefotaxime formulations?

Operational and regulatory execution: manufacturing scale and redundancy, sterile quality performance, and lifecycle approval speed tied to container and stability proof.

---

References

[1] ClinicalTrials.gov. (n.d.). Cefotaxime studies. https://clinicaltrials.gov/
[2] FDA. (n.d.). Drug approvals and labeling resources for cephalosporin injectables. https://www.accessdata.fda.gov/
[3] EMA. (n.d.). European public assessment reports for cephalosporin products. https://www.ema.europa.eu/